Marinomed – First Covid patient treated with Carragelose-based inhalation solution


Marinomed Biotech has now treated the first patient as part of a clinical study examining a Carragelose-based inhalation solution (Inhaleen) in hospitalized patients with Covid-19. “With this study, we want to show that Inhaleen is an effective treatment option for patients who recently had to be hospitalized for Covid-19. In addition, we want to prove that Inhaleen can contribute to a faster recovery and prevent the disease The patient’s lungs continue to be damaged or become more severe, “explains Marinomed CSO Eva Prieschl-Grassauer.

The study is being carried out at three hospitals in Vienna, Austria, namely the Karl Landensteiner Institute for Lung Research and Pneumological Oncology at the Floridsdorf Clinic, the Favoriten Clinic and the Ottakring Clinic.

Photo credit

1. Coronavirus, mask, virus – (Image: Gerd Altmann >> Open on

Stocks on the radar:Telekom Austria, Zumtobel, OMV, Mold, Kapsch TrafficCom, FACC, Semperit, Vienna Airport, Uniqa, Palfinger, RBI, Composite, Rosenbauer, Frequentis, Athos real estate, Oberbank AG trunk, Andritz, In fact, CA, Strabag, Wienerberger, Warimpex, E.ON , Continental, SAP, Volkswagen Vz., HeidelbergCement, Henkel, Teamviewer, GameStop, Fabasoft, EVN.

Random Partner

Frequentis, headquartered in Vienna, is an international provider of communication and information systems for control centers with security-critical tasks. Frequentis develops and sells such “Control Center Solutions” in the segments Air Traffic Management (civil and military air traffic control, air defense) and Public Safety & Transport (police, fire brigade, rescue services, shipping, rail).

>> Visit 61 other partners at

Coronavirus, mask, virus – (Image: Gerd Altmann


Christine Petzwinkler

Börse Social Network/Magazine


Read original article here

Leave a Comment